Lambropoulos S, Chatzipappas A, Tsekos G, Tsantoulis K
Eur J Respir Dis Suppl. 1986;146:657-61.
Sixteen (16) C.O.L.D. patients with acute respiratory failure entered this preliminary study to evaluate the effects of almitrine bismesylate against placebo. Eight (8) patients received almitrine bismesylate and eight (8) patients received placebo. During the study, (11) patients were intubated and one (1) patient died because of bleeding peptic ulceration. A significant improvement in PaO2 values was noted in the patients given almitrine bismesylate as opposed to those given placebo. This improvement (p = 0.032) became evident on the 2nd day of treatment. The changes in PaO2 levels were not modified by intubation. A surprising evolution of PaCO2 was observed in those patients given almitrine bismesylate whether or not they had been intubated. No side effects were noted in the patients taking almitrine bismesylate during the first 4 days of the trial or during the following 6 days when patients continued to receive almitrine bismesylate.
16例患有急性呼吸衰竭的慢性阻塞性肺病（C.O.L.D.）患者进入了这项初步研究，以评估二甲磺酸阿米三嗪对比安慰剂的效果。8例患者接受了二甲磺酸阿米三嗪治疗，8例患者接受了安慰剂治疗。在研究期间，11例患者进行了气管插管，1例患者因消化性溃疡出血死亡。与接受安慰剂的患者相比，接受二甲磺酸阿米三嗪治疗的患者的动脉血氧分压（PaO2）值有显著改善。这种改善（p = 0.032）在治疗第2天变得明显。气管插管并未改变PaO2水平的变化。在接受二甲磺酸阿米三嗪治疗的患者中，无论是否进行了气管插管，均观察到动脉血二氧化碳分压（PaCO2）出现了令人惊讶的变化。在试验的前4天以及随后患者继续接受二甲磺酸阿米三嗪治疗的6天里，服用二甲磺酸阿米三嗪的患者未出现任何副作用。
